3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Conditions
Carcinoma, Hepatocellular
59
Cholangiocarcinoma
19
Carcinoma, Renal Cell
16
Biliary Tract Neoplasms
11
Stomach Neoplasms
9
Thyroid Neoplasms
8
Endometrial Neoplasms
8
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Neoplasms
7
Melanoma
6
Uterine Cervical Neoplasms
5
Thyroid Carcinoma, Anaplastic
5
Neuroendocrine Tumors
5
Carcinoma, Non-Small-Cell Lung
5
Recurrence
4
Ovarian Neoplasms
4
Liver Neoplasms
4
Thyroid Cancer, Papillary
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Neoplasm Metastasis
3
Cirrhosis, Familial, with Pulmonary Hypertension
3
Brain Neoplasms
3
Advanced Biliary Tract Cancer
3
Adenocarcinoma, Follicular
3
Vulvar Neoplasms
2
Uveal Melanoma
2
Triple Negative Breast Neoplasms
2
Thymoma
2
Solid Tumors
2
Interventions
pembrolizumab
6
Cisplatin
5
Radiotherapy
4
Paclitaxel
3
Nivolumab
3
lenvatinib
2
Specimen Handling
2
Platinum
2
Papillomavirus Vaccines
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
Gemcitabine
2
Carboplatin
2
CTLA-4 Antigen
2
Bleomycin
2
Bevacizumab
2
1,2-diaminocyclohexaneplatinum II citrate
2
zimberelimab
1
rocakinogene sifuplasmid
1
liposomal doxorubicin
1
durvalumab
1
dostarlimab
1
cemiplimab
1
belzutifan
1
antineoplaston AS 2-1
1
antineoplaston A10
1
alovudine
1
aldesleukin
1
Watchful Waiting
1
Vorinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Vulvar Neoplasms
×
lenvatinib
×
Clear all
NCT05903833
2026-05-11
PIERCE
AGO Research GmbH
Phase 2
Recruiting
42 enrolled
NCT07290894
2026-04-02
MITO VULVA-01
National Cancer Institute, Naples
Phase 2
Recruiting
80 enrolled